Methods of inhibiting prmt5
US-2015344457-A1 · Dec 3, 2015 · US
PRMT1 inhibitors and uses thereof
US9475776B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9475776-B2 |
| Application number | US-201514675781-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 1, 2015 |
| Priority date | Mar 14, 2013 |
| Publication date | Oct 25, 2016 |
| Grant date | Oct 25, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a PRMT1-mediated disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of: and pharmaceutically acceptable salts thereof. 2. The method of claim 1 , wherein the PRMT1-mediated disorder is a proliferative disorder. 3. The method of claim 2 , wherein the proliferative disorder is cancer. 4. The method of claim 1 , wherein the PRMT1-mediated disorder is a neurological disorder. 5. The method of claim 4 , wherein the neurological disorder is amyotrophic lateral sclerosis. 6. The method of claim 1 , wherein the PRMT1-mediated disorder is a muscular dystrophy. 7. The method of claim 1 , wherein the PRMT1-mediated disorder is an autoimmune disorder. 8. The method of claim 1 , wherein the PRMT1-mediated disorder is a vascular disorder. 9. The method of claim 1 , wherein the PRMT1-mediated disorder is a metabolic disorder.
Assignees
Inventors
Classifications
- C07D231/12Primary
with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms · CPC title
Antineoplastic agents · CPC title
Drugs for immunological or allergic disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9475776B2 cover?
- Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting PRMT1 activity. Methods of using the compounds for treating PRMT1-mediated disorders are also described.
- Who is the assignee on this patent?
- Epizyme Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D231/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).